Shanghai Haohai Biological Technology Co., Ltd. (6826.HK)
HKD 26.85
(-1.65%)
HKD 26.85
(-1.65%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 407.94 Million CNY | 244.97% |
| 2022 | 118.25 Million CNY | 12.08% |
| 2021 | 105.51 Million CNY | -2.38% |
| 2020 | 108.08 Million CNY | 117.41% |
| 2019 | 49.71 Million CNY | 35.62% |
| 2018 | 36.65 Million CNY | -2.21% |
| 2017 | 37.48 Million CNY | 40.57% |
| 2016 | 26.66 Million CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 424.18 Million CNY | 99.31% |
| 2024 Q1 | 212.82 Million CNY | -47.83% |
| 2023 Q3 | 275 Million CNY | 19.28% |
| 2023 FY | 407.94 Million CNY | 244.97% |
| 2023 Q1 | 212.99 Million CNY | 80.11% |
| 2023 Q2 | 230.55 Million CNY | 8.24% |
| 2023 Q4 | 407.94 Million CNY | 48.34% |
| 2022 Q4 | 118.25 Million CNY | 0.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q2 | 75.2 Million CNY | 22.12% |
| 2022 Q1 | 61.58 Million CNY | -41.63% |
| 2022 FY | 118.25 Million CNY | 12.08% |
| 2021 Q1 | 55.09 Million CNY | -49.02% |
| 2021 Q2 | 66.39 Million CNY | 20.5% |
| 2021 Q3 | 89.95 Million CNY | 35.5% |
| 2021 Q4 | 105.51 Million CNY | 17.29% |
| 2021 FY | 105.51 Million CNY | -2.38% |
| 2020 Q3 | 124.47 Million CNY | 11.35% |
| 2020 FY | 108.08 Million CNY | 117.41% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 108.08 Million CNY | -13.17% |
| 2020 Q2 | 111.79 Million CNY | 0.0% |
| 2019 Q4 | 49.71 Million CNY | 0.0% |
| 2019 FY | 49.71 Million CNY | 35.62% |
| 2019 Q2 | 79.39 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q2 | 38.99 Million CNY | 0.0% |
| 2018 Q4 | 36.65 Million CNY | 0.0% |
| 2018 Q1 | 38.99 Million CNY | 4.04% |
| 2018 Q3 | 36.65 Million CNY | -6.01% |
| 2018 FY | 36.65 Million CNY | -2.21% |
| 2017 Q3 | 37.48 Million CNY | 57.67% |
| 2017 FY | 37.48 Million CNY | 40.57% |
| 2017 Q1 | 25.16 Million CNY | -5.61% |
| 2017 Q2 | 23.77 Million CNY | -5.55% |
| 2017 Q4 | 37.48 Million CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 Q3 | 26.66 Million CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2016 FY | 26.66 Million CNY | 0.0% |
| 2016 Q4 | 26.66 Million CNY | 0.0% |
| 2015 Q3 | - CNY | 0.0% |
| 2015 Q2 | - CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | - CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 52.86 Million HKD | -671.652% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.93 Billion HKD | 93.122% |